SETD1A function in leukemia is mediated through interaction with mitotic regulators BuGZ/BUB3

Abstract

The H3K4 methyltransferase SETD1A plays a crucial role in leukemia cell survival through its noncatalytic FLOS domain‐mediated recruitment of cyclin K and regulation of DNA damage response genes. In this study, we identify a functional nuclear localization signal in and interaction partners of the FLOS domain. Our screen for FLOS domain‐binding partners reveals that the SETD1A FLOS domain binds mitosis‐associated proteins BuGZ/BUB3. Inhibition of both cyclin K and BuGZ/BUB3‐binding motifs in SETD1A shows synergistic antileukemic effects. BuGZ/BUB3 localize to SETD1A‐bound promoter‐TSS regions and SETD1A‐negative H3K4me1‐positive enhancer regions adjacent to SETD1A target genes. The GLEBS motif and intrinsically disordered region of BuGZ are required for both SETD1A‐binding and leukemia cell proliferation. Cell‐cycle‐specific SETD1A restoration assays indicate that SETD1A expression at the G1/S phase of the cell cycle promotes both the expression of DNA damage response genes and cell cycle progression in leukemia cells.

Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma

“…The overexpression of ZNF207 has been significantly associated with poor clinical outcomes in liver malignancies. Previous studies revealed the involvement of ZNF207 in the modulation of stem cell self-renewal and pluripotency, as well as its influence on chromosome arrangement. ,, Inhibiting ZNF207 affects the BUB3 mitotic checkpoint protein (BUB3) and BUB1 mitotic checkpoint serine/threonine kinase (BUB1) kinetochore localization, causing defects in spindle formation in GSCs and other transformed cells but not in human neural stem cells or nontransformed ones. Moreover, it has been observed that in p53-deficient CSCs, targeting ZNF207 might enhance the sensitivity of tumor cells to cisplatin by inhibiting spindle assembly checkpoints .…”